Randomized phase III study of Gemcitabine/cisplatin versus mitomycin/ifosfamide/cisplatin in advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Scagliotti, G
Crino, L
Conte, PF
Rinaldi, M
De Marinis, F
Gridelli, C
机构：
[1] Univ Turin, Dept Clin & Biol Sci, Turin, Italy
[2] Osped Policlin, Div Med Oncol, Perugia, Italy
[3] St Chiara Hosp, Div Med Oncol, Pisa, Italy
[4] Med Oncol, Rome, Italy
[5] Dept Pneumol, Rome, Italy
[6] Natl Canc Inst, Naples, Italy
来源：
ANNALS OF ONCOLOGY | 1998年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
407P
引用
收藏
页码：85 / 85
页数：1
相关论文
共 50 条
  • [1] Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer:: A randomized phase III study of the Italian lung cancer project
    Crinò, L
    Scagliotti, GV
    Ricci, S
    De Marinis, F
    Rinaldi, M
    Gridelli, C
    Ceribelli, A
    Bianco, R
    Marangolo, M
    Di Costanzo, F
    Sassi, M
    Barni, S
    Ravaioli, A
    Adamo, V
    Portalone, L
    Cruciani, G
    Masotti, A
    Ferrara, G
    Gozzelino, F
    Tonato, M
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (11) : 3522 - 3530
  • [2] Rationale of a phase III study comparing a standard cisplatin regimen (mitomycin/ifosfamide/cisplatin) with cisplatin and gemcitabine in non-small cell lung cancer
    Tonato, M
    Crino, L
    Mosconi, AM
    SEMINARS IN ONCOLOGY, 1997, 24 (03) : 831 - 835
  • [3] Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer
    Chen, YM
    Perng, RP
    Whang-Peng, J
    Wu, HW
    Lin, WC
    Tsai, CM
    LUNG CANCER, 2000, 30 (03) : 199 - 202
  • [4] Phase II study of Gemcitabine, ifosfamide and cisplatin (GIP) in patients with advanced non-small cell lung cancer (NSCLC)
    De las Penas, R
    Busquier, I
    Munarriz, J
    Lopez, A
    Llorente, R
    Alberola, V
    Frau, A
    ANNALS OF ONCOLOGY, 1998, 9 : 88 - 88
  • [5] Gemcitabine/carboplatin (GC) versus mitomycin/ifosfamide/cisplatin (MIP): A randomised comparison in patients with advanced non-small cell lung cancer (NSCLC)
    Gower, NH
    Rudd, RM
    James, LE
    Gregory, W
    Eisen, T
    Lee, SM
    Harper, PG
    Spiro, SG
    BRITISH JOURNAL OF CANCER, 2002, 86 : S1 - S1
  • [6] Gemcitabine and cisplatin for advanced non-small cell lung cancer (NSCLC)
    Casal, J
    Grande, C
    Caeiro, M
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1083 - 1083
  • [7] Phase II study of Gemcitabine in combination with cisplatin and ifosfamide in advanced non-small cell lung cancer
    Mohedano, N
    Medina, MB
    Sanchez, P
    Jaen, A
    Gonzalez, E
    Porras, I
    Fernandez, M
    Lozano, A
    ANNALS OF ONCOLOGY, 1998, 9 : 90 - 90
  • [8] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [9] Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: An implementation study
    Meert, A
    Berghmans, T
    Ninane, V
    Sculier, J
    LUNG CANCER, 2005, 49 : S258 - S258
  • [10] Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma
    Danson, S
    Middleton, MR
    O'Byrne, KJ
    Clemons, M
    Ranson, M
    Hassan, J
    Anderson, H
    Burt, PA
    Fairve-Finn, C
    Stout, R
    Dowd, I
    Ashcroft, L
    Beresford, C
    Thatcher, N
    CANCER, 2003, 98 (03) : 542 - 553
12345